News
The financing will enable Nova Anchora to advance its lead candidate NvA-011, a recombinant collagen therapy, through IND-enabling studies. The investment underscores the backers’ commitment to ...
MUNICH, Germany and SAN FRANCISCO ... The investment will support the development of Nova Anchora’s lead candidate, NvA-011, through preclinical development and to IND readiness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback